Antibody drug conjugates (ADCs) are formed by attaching drug substances to antibodies using a special linker moiety. The ideal ADC will specifically target antigen-expressing cells and release the drug in active form inside the cell. ADCs combine the specificity of monoclonal antibodies with high potency of cytotoxic drugs, leading to highly improved therapeutic efficacy and less side effects. However, the current challenges in ADC technology are related to creating highly homogeneous ADC products with high drug-to-antibody ratio as well as applying the technology to various drug substances.
Glykos’ breakthrough ADC technology utilizes novel hydrophilic linkers with both cleavable and non-cleavable variants as well as site-specific conjugation to glycans or cysteines. The benefits include homogeneous drug-to-antibody ratio (DAR), high utility with hydrophobic drugs, and significantly improved payload efficacy particularly against drug-resistant cells and low-abundance target antigens.
Our linkers can be used with practically any monoclonal antibody and with a large selection of potent toxins making our technology highly flexible as it can be integrated into our clients existing development programs.